Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Peñarrubia, J.
Right arrow Articles by A.Vanrell, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peñarrubia, J.
Right arrow Articles by A.Vanrell, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 14, No. 7, 1703-1706, July 1999
© 1999 European Society of Human Reproduction and Embryology

Recurrent empty follicle syndrome successfully treated with recombinant human chorionic gonadotrophin: Case report

Joana Peñarrubia, Juan Balasch1, Francisco Fábregues, Montserrat Creus, Salvadora Cívico and Juan A.Vanrell

Institut Clínic of Gynecology, Obstetrics and Neonatology; Faculty of Medicine-University of Barcelona, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Suynyer (IDIBAPS), C/Casanova 143, 08036 Barcelona, Spain

We report a case of a patient with polycystic ovary syndrome and primary infertility who was admitted to our in-vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) programme because of her partner's severe oligozoospermia and asthenozoospermia. Ovarian stimulation was accomplished in the three treatment cycles using gonadotrophin therapy after a dual approach with ovarian suppression using oral contraceptive pills followed by gonadotrophin-releasing hormone agonist therapy. Oocyte retrieval was unsuccessful in the first two treated cycles despite the fact that human chorionic gonadotrophin (HCG) from three different batches was used. In the third treatment cycle, recombinant HCG was used and five oocytes were retrieved. This is the first report of recurrent empty follicle syndrome despite the use of different batches of commercially available urinary HCG, and of its successful treatment using recombinant HCG.

Key words: empty follicle syndrome/HCG/in-vitro fertilization/recombinant gonadotrophins/recombinant HCG

1 To whom correspondence should be addressed


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
H. Al-Inany, M. A. Aboulghar, R. T. Mansour, and M. Proctor
Recombinant versus urinary gonadotrophins for triggering ovulation in assisted conception
Hum. Reprod., August 1, 2005; 20(8): 2061 - 2073.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
F. Lok, J. Pritchard, and H. Lashen
Successful treatment of empty follicle syndrome by triggering endogenous LH surge using GnRH agonist in an antagonist down-regulated IVF cycle
Hum. Reprod., October 1, 2003; 18(10): 2079 - 2081.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
The European Recombinant Human Chorionic Gonadotro
Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment--recombinant HCG versus urinary HCG
Hum. Reprod., July 1, 2000; 15(7): 1446 - 1451.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.